Parkinson s Disease - A Junior Doctor s Survival Guide
|
|
|
- Sarah Barker
- 10 years ago
- Views:
Transcription
1 Parkinson s Disease - A Junior Doctor s Survival Guide Professor Richard Walker Consultant Geriatrician Hon. Professor of Ageing & Interna<onal Health Northumbria Healthcare NHS Founda<on Trust
2 Geriatricians ideally suited to care for Parkinson s disease Ø Many patients elderly Ø Multiple co-morbidity Ø Multi-system disease Ø Requires multidisciplinary team
3 North Tyneside Prevalence Ø Population of 110,000. Ø Case finding hospital records, GP records (diagnostic lists and drug treatment), other hospitals (eg Neurology). Ø Age-standardised prevalence = 160/100,000. Comparable with previous studies (Porter et al 2006).
4 Aetiological theory for PD
5 What causes Parkinson s? Ageing Genes Environment Parkinson s disease Possible protective effect: smoking and caffeine
6 When do clinical signs of Parkinson's develop? Striatal dopamine levels Reduced by 80% Cell loss in the substantia nigra Reaches 50%
7 The Braak hypothesis Stage 5 and 6: Changes spread to the cortex Stage 3 and 4: Pathology spreads to the midbrain and basal ganglia Stage 1 and 2: Pathology confined to certain structures in the brain stem, not yet the substantia nigra Image adapted from The Professionals Guide to Parkinson s Disease
8 DIAGNOSIS
9 Differential Diagnoses Ø Drug induced parkinsonism Ø Cerebrovascular parkinsonism Ø Lewy body dementia Ø Alzheimers disease Ø Multi system atrophy Ø Progressive supranuclear palsy Ø Benign essential tremor Ø Other weird and wonderful conditions
10 Brain Bank Criteria Ø Developed by PD society brain bank study Ø Retrospectively Ø Sensitivity 96% Ø Specificity 82% Ø Tool now used in epidemiological studies in PD
11 Diagnosis of Parkinsonism - signs Ø BRADYKINESIA and one of: Ø Muscular rigidity Ø 4-6Hz rest tremor Ø Postural instability
12 Probable most important diagnostic criteria Ø Asymmetrical onset Ø Progressive condition Ø Responsive to levodopa
13 Speech Hypomimia Reduced arm swing Posture Tremor Arising from a chair Bradykinesia Rigidity Motor symptoms of Parkinson s Motor symptoms of Parkinson's Postural instability Micrographia Turning in bed Turning Freezing Gait festination Shuffling gait Falls
14 Investigations Ø Routine blood investigations Ø DAT Scan normal in essential tremor and drug-induced Parkinsonism Ø +/- MRI Scan Ø?Dopamine challenge reasonable dose for reasonable length of time Ø Sniffin sticks objective change in sense of smell at diagnosis in over 70%
15 Partnerships in PD PDS Service Users Carers Age Concern Voluntary Bodies Family Health Visitor Consultant Social Worker Person with PD Friends Physiotherapy PD Nurse OT Dietician Psychiatrist GP District Nurse SALT Psychologist
16 The most important partnership Person with PD Person who knows about PD
17 Drug classes in Parkinson s Levodopa MAO-B inhibitors Monoamine oxidase B inhibitors Anticholinergics DAs Dopamine agonists COMTs Catechol-Omethyltransferase inhibitors
18 L-dopa Benefits Disadvantages Most effective symptomatic therapy Good response for morbidity and probably mortality Benefits may be enhanced by: Ø dopamine agonists Ø CR preparations Ø COMT inhibitors Short and long term side effects Complications with longterm use include motor fluctuations and dyskinesias Do not stop disease progression Free radical formation?
19 Specifics of L dopa prescribing Ø Sinemet 110, 125, 275 Halfs etc etc Ø Start low go slow Ø What dose do you go to? Ø CR preparations Ø Dispersible madopar
20 Typical pattern of wearingoff during the day
21 Dopamine agonists Benefits Disadvantages Proven antiparkinsonian activity, although less than levodopa Motor fluctuations and dyskinesias are encountered less if monotherapy Do not produce free radicals Initiation of treatment requires careful dose titration Limited evidence for add on therapy Non-ergolines (ropinirole/ pramipexole) can cause confusion (particularly in the elderly), nausea, dizziness, fainting and daytime sleepiness Ergot-derived agonists (cabergoline, bromocriptine and pergolide) can cause additional, lung and peritoneal fibrosis now not used
22 Impulse Control Disorder A person s inability to resist a temptation or impulse More likely to happen in those with a previous history of novelty seeking or risk taking behaviours Compulsive behaviours have been reported as a side effect with levodopa and dopamine agonists Behaviours can include: l Pathological gambling l Hypersexuality l Compulsive eating l Compulsive shopping l Punding
23 Ø Thalamotomy l Surgery drug-resistant unilateral tremor Ø Pallidotomy l drug-induced dyskinesias Ø Sub-thalamotomy - experimental Ø Stimulation - bilateral l l l thalamic (tremor) bilateral subthalamic nucleus (parkinsonism, tremor, dystonia) pallidal (dyskinesias)
24 Non-motor symptoms Neuropsychiatric Autonomic Sleep disturbance Sensory symptoms Dementia Depression Apathy Anxiety Loss of libido REM sleep disorder RLS Vivid dreams Daytime somnolence Dystonia Constipation Urinary incontinence Erectile dysfunction Excessive sweating Postural hypotension Excessive salivation Pain Paraesthesia
25 Sleep Disorders Ø Two thirds of patients Ø Insomnia l l Initial Sleep maintenance (sleep fragmentation) Parasomnias l l REM sleep behaviour disorder Vivid dreams Ø Excessive daytime sleepiness and sleep attacks Ø Obstructive sleep apnoea and stridor (NB MSA)
26 NEUROPSYCHIATRIC COMPLICATIONS
27 Ø Depression Ø Anxiety and agitation Ø Sleep disturbances Ø Vivid dreams Ø Hallucinations Ø Delirium Ø Dementia
28 Confused patient Ø Delirium screen Ø Decrease PD medication in following order l Anticholinergic, Amantadine, MAOIB, DA, COMT-I, LD Ø Consider atypical neuroleptic, eg Quetiapine (Clozapine) start at low dose of 12.5mgs Ø Cholinesterase inhibitors, eg Donepezil, Rivastigmine (NB patch) may improve cognition and hallucinations
29 Swallowing problems Ø Look for reversible cause Ø Get PD medication into patient l NG tube l Rotigotine patch l Apomorphine subcutaneously (NB Domperidone) Ø Don t consider for end of life care unless adequate dopaminergic replacement, or on advice from PD specialist team
30 General tips for inpatients Ø Make sure they get medication on time Ø Know how to contact PD specialist team, eg PD nurse specialist will often know patients well Ø Ask about hallucinations Ø Any illness will often make PD symptoms worse, and it takes PD patients longer to recover
31 Useful Contacts for PD Ø Parkinson s UK Ø BGS movement disorders section Ø [email protected]
What is PD? Dr Catherine Dotchin MD MRCP Consultant Geriatrician
What is PD? Dr Catherine Dotchin MD MRCP Consultant Geriatrician Overview of presentation Case history Video example pre and post treatment Historical review PD in the UK Epidemiology and aetiology Making
Dementia & Movement Disorders
Dementia & Movement Disorders A/Prof Michael Davis Geriatrician ACT Health & GSAHS ANU Medical School Eastern Dementia Network Aged and Dementia Care Symposium Bateman s Bay, 22 October 2010 Types of Dementia
PARKINSON S DISEASE AND PARKINSONISM. Dr Phil Wood Geriatrician, Waitemata DHB Clinical Unit Leader, Waikato DHB
PARKINSON S DISEASE AND PARKINSONISM Dr Phil Wood Geriatrician, Waitemata DHB Clinical Unit Leader, Waikato DHB OUTLINE Covering:- Why this is an important area of Medical and Psychiatric care The variety
CENTRAL NERVOUS SYSTEM MANAGEMENT OF PARKINSON S DISEASE
MANAGEMENT CENTRAL NERVOUS SYSTEM MANAGEMENT OF PARKINSON S DISEASE Parkinson s Disease is classically determined by the triad or rest tremor (usually starting in one arm) with bradykinesia (slowing of
Management of Parkinson s Disease in Primary Care
Management of Parkinson s Disease in Primary Care Dr June Tan National University Hospital System (NUHS) Division of Neurology Senior Consultant Topics: Diagnosing PD Choice of medication in the de novo
Parkinson s Disease and Dementia. Dr N Samaniego Consultant Physician and Geriatrician
Parkinson s Disease and Dementia Dr N Samaniego Consultant Physician and Geriatrician Case 68 year old female. Off legs for a few months, O/E no neurological deficit. -Slowing down -Needs help with dressing,
GLOSSARY OF TERMS. This glossary explains the terms and words often used in association with Parkinson s.
Antagonist This glossary explains the terms and words often used in association with Parkinson s. Medications which have a negative effect on particular cells in the body. In Parkinson s dopamine antagonists
Doncaster & Bassetlaw Medicines Formulary
Doncaster & Bassetlaw Medicines Formulary Section 4.9: Drugs Used in Parkinsonism and related Disorders Co-Beneldopa 12.5/50, 25/100 and 50/200 (Madopar) Capsules Co-Beneldopa 12.5/50 and 25/100 Dispersible
Lewy body dementia Referral for a Diagnosis
THE Lewy Body society The more people who know, the fewer people who suffer Lewy body dementia Referral for a Diagnosis Lewy Body Dementias REFERRAL FOR A DIAGNOSIS In the UK people with all forms of dementia
Parkinson's s disease - a
Parkinson's Disease Parkinson's s disease - a progressive disorder of the nervous system that affects movement. The most common perception of Parkinson s is the patient having tremors. Hands shaking, inability
The majority of parkinsonism (approx. 80%) is due to idiopathic PD other causes include drug therapy (Table 1),toxins and trauma.
THE TREATMENT OF PARKINSON S DISEASE SUMMARY Levodopa (L-dopa) administered in conjunction with a dopa decarboxylase inhibitor (DDCI) remains the mainstay of therapy for Parkinson s disease. New drugs
An Introduction to Lewy Body Dementia
An Introduction to Lewy Body Dementia A special publication for people newly diagnosed with Lewy body dementia and those still seeking answers. You don t have to face LBD alone. Increasing Knowledge Sharing
Emergency Room Treatment of Psychosis
OVERVIEW The term Lewy body dementias (LBD) represents two clinical entities dementia with Lewy bodies (DLB) and Parkinson s disease dementia (PDD). While the temporal sequence of symptoms is different
How To Treat Aphasic Depression
Antipsychotic Use in Patients with Parkinson s Disease 단국의대 정신과 이석범 Difficulties in Parkinson's disease Motor symptoms Neuropsychiatric syndromes Severe Disability Cognitive impairment 2 Neuropsychiatric
Acute management of Parkinson s
Acute management of Parkinson s Fife Parkinson s Service 2013 1 Contents 1. Introduction 2. On admission to hospital 3. If Patient has compromised swallow or is nil by mouth 4. Conversion charts if patient
Personal Health Record
Personal Health Record Contents Section 1: Personal details (pages 4 6) Within this section you can note all information about you, next of kin, important health information and general medical history.
Motor Fluctuations in Parkinson s
Motor Fluctuations in Parkinson s What are motor fluctuations? Motor fluctuations are associated with longterm use of levodopa (trade names Sinemet or Madopar, Co-careldopa or Co-beneldopa), and usually
Chapter 28. Drug Treatment of Parkinson s Disease
Chapter 28 Drug Treatment of Parkinson s Disease 1. Introduction Parkinsonism Tremors hands and head develop involuntary movements when at rest; pin rolling sign (finger and thumb) Muscle rigidity arthritis
PARKINSON S DISEASE IN LONG-TERM-CARE SETTINGS
PARKINSON S DISEASE IN LONG-TERM-CARE SETTINGS De Anna Looper, RN CHPN Corporate Clinical Consultant / Legal Nurse Consultant Carrefour Associates L.L.C. PARKINSON S DISEASE IN LONG-TERM-CARE SETTINGS
PARKINSON S DISEASE INTRODUCTION. Parkinson s disease is defined as a disease of the nervous system that affects voluntary movement.
PARKINSON S DISEASE INTRODUCTION Parkinson s disease is a disorder of the brain and the nervous system. It is one of the more common neurological diseases in people over the age of 60, and it is more common
Multiple System Atrophy guide (http://www.msaweb.co.uk/msaguide.htm)
Multiple System Atrophy guide (http://www.msaweb.co.uk/msaguide.htm) Accessing information on Multiple System Atrophy (MSA) can be hard work. The Sarah Matheson Trust (SMT) produces a guide to MSA that
SLEEP AND PARKINSON S DISEASE
A Practical Guide on SLEEP AND PARKINSON S DISEASE MICHAELJFOX.ORG Introduction Many people with Parkinson s disease (PD) have trouble falling asleep or staying asleep at night. Some sleep problems are
Clinical Psychopharmacology
Clinical Psychopharmacology Antiparkinsonian drugs Department of Pharmacy, GGZ WNB Chair on Pharmacotherapy in Psychiatric Patients/Anton Loonen May 2015 2 Basal ganglia diseases Parkinson s disease and
Parkinson s Disease Symptoms Guide
Parkinson s Disease Symptoms Guide Some symptoms of Parkinson s disease (PD) are hard for even specialists to detect. Others are obvious even to an untrained eye. Parkinson s symptoms are different for
Disordered sleep at night has long been
Neurology 59 Excessive daytime sleepiness in PD Excessive Daytime Sleepiness (EDS) in Parkinson s disease (PD) is an important issue that warrants serious attention because it can have adverse effects
Parkinson s Disease: Factsheet
Parkinson s Disease: Factsheet Tower Hamlets Joint Strategic Needs Assessment 2010-2011 Executive Summary Parkinson s disease (PD) is a progressive neuro-degenerative condition that affects a person s
Diagnosis and Treatment of Parkinson s Disease: A Systematic Review of the Literature
Evidence Report/Technology Assessment Number 57 Diagnosis and Treatment of Parkinson s Disease: A Systematic Review of the Literature Prepared for: Agency for Healthcare Research and Quality U.S. Department
drug treatments for parkinson s
drug treatments for parkinson s While there is no cure yet for Parkinson s, there are many different drugs that can help manage the symptoms. This booklet is for people with Parkinson s and their families.
Anti-Parkinsonism Drugs
Anti-Parkinsonism Drugs Pharma Team 429 Fahad Alrumaih Ibrahim Alshiddi Sultan Alsalem Ismail Raslan Suhail Asiri Parkinsonism - Could be: primary [idiopathic] or secondary [viral infection or drug induced
PARKINSONISM. akinetic-rigid syndrome
PARKINSONISM PARKINSONISM akinetic-rigid syndrome PARKINSONISM Symptoms of Parkinson s disease: akinesia, bradykinesia, rigidity, postural instability, gait impairment, tremor A common, age-related syndrome
NEW PATIENT CLINICAL INFORMATION FORM. Booth Gardner Parkinson s Care & Movement Disorders Center Evergreen Neuroscience Institute
NEW PATIENT CLINICAL INFORMATION FORM Booth Gardner Parkinson s Care & Movement Disorders Center Evergreen Neuroscience Institute Date: Name: Referring Doctor: How did you hear about us? NWPF Your Physician:
Current evidence suggests that Parkinson s tends to develop
About Parkinson's Diagnosing Parkinson s Current evidence suggests that Parkinson s tends to develop gradually and it may be many months, even years, before the symptoms become obvious enough for you to
Unmet Needs for Parkinson s Disease Therapeutics
Unmet Needs for Parkinson s Disease Therapeutics Coalition Against Major Diseases & FDA Workshop October 20, 2014 Caroline M Tanner MD, PhD Director, Parkinson's Disease Research Education and Clinical
Parkinson s Disease (PD)
Parkinson s Disease (PD) Parkinson s disease (PD) is a movement disorder that worsens over time. About 1 in 100 people older than 60 has Parkinson s. The exact cause of PD is still not known, but research
Donepezil hydrochloride (Aricept) Drug treatment for Alzheimer s disease
IS 11 October 2011 Information sheet Donepezil hydrochloride (Aricept) Drug treatment for Alzheimer s disease Introduction... 1 How does Aricept work?... 1 Who might benefit from Aricept?... 2 What effect
Ronald Postuma, Christos Galatas. A Guide to the Non-Motor Symptoms. Parkinson s Disease. A patient-friendly booklet for:
Ronald Postuma, Christos Galatas A Guide to the Non-Motor Symptoms of Parkinson s Disease A patient-friendly booklet for: This booklet is to help you understand Parkinson s Disease and prepare for the
Dementia with Lewy bodies
IS 18 April 2011 Information sheet Dementia with Lewy bodies Introduction... 1 Key points... 1 What is dementia with Lewy bodies?... 1 How many people are affected by DLB?.. 2 What is the cause?... 2 Symptoms...
Levels of evidence and grades of recommendation
MOH Clinical Practice Guidelines 6/2007 Levels of evidence and grades of recommendation Levels of Evidence Level Type of Evidence 1 ++ High quality meta analyses, systematic reviews of RCTs, or RCTs with
NEUROIMAGING in Parkinsonian Syndromes
NEUROIMAGING in Parkinsonian Syndromes (Focus on Structural Techniques: CT and MRI) Dr. Roberto Cilia Parkinson Institute, ICP, Milan, Italy OUTLINE Primary Parkinsonism Idiopathic Parkinson s Disease
PARKINSON'S DISEASE The Disorder and Current Therapy Copyright 2008, Daniel Kassicieh, D.O.
PARKINSON'S DISEASE The Disorder and Current Therapy Copyright 2008, Daniel Kassicieh, D.O. Parkinson's disease is a common neurologic disorder. It affects people of all ages and ethnic backgrounds and
Sleep Difficulties. Insomnia. By Thomas Freedom, MD and Johan Samanta, MD
Sleep Difficulties By Thomas Freedom, MD and Johan Samanta, MD For most people, night is a time of rest and renewal; however, for many people with Parkinson s disease nighttime is a struggle to get the
These guidelines are intended to support General Practitioners in the care of their patients with dementia both in the community and in care homes.
This is a new guideline. These guidelines are intended to support General Practitioners in the care of their patients with dementia both in the community and in care homes. It incorporates NICE clinical
COMPASS Therapeutic Notes on Management of Parkinson s Disease
COMPASS Therapeutic Notes on Management of Parkinson s Disease In this issue Page Introduction 1 Drug Treatment in 3 early PD Motor 9 complications Depression in PD 11 Dementia in PD 13 Psychosis in PD
III./3.1.2. Parkinsonian syndrome (parkinsonism, atypical parkinsonian disorders) in neurodegenerative diseases
III./3.1.2. Parkinsonian syndrome (parkinsonism, atypical parkinsonian disorders) in neurodegenerative diseases III./3.1.2.1. Multiple System Atrophy (MSA) MSA is a sporadic, adult onset degenerative neurological
SLEEP DIFFICULTIES AND PARKINSON S DISEASE Julie H. Carter, R.N., M.S., A.N.P.
SLEEP DIFFICULTIES AND PARKINSON S DISEASE Julie H. Carter, R.N., M.S., A.N.P. Problems with sleep are common in Parkinson s disease. They can sometimes interfere with quality of life. It is helpful to
Parkinson's disease. Definition. Symptoms
Parkinson's disease Definition Parkinson's disease is a progressive disorder of the nervous system that affects your movement. It develops gradually, sometimes starting with a barely noticeable tremor
drug treatments for parkinson s
drug treatments for parkinson s 1 While there is no cure yet for Parkinson s, there are many different drugs that can help manage the symptoms. This booklet is for people with Parkinson s and their families.
SUMMARY OF RECOMMENDATIONS
SUMMARY OF RECOMMENDATIONS FOR THE LONG- TERM TREATMENT OF RLS/WED from AN IRLSSG TASK FORCE Members of the Task Force Diego Garcia- Borreguero, MD, Madrid, Spain* Richard Allen, PhD, Baltimore, MD, USA*
How To Treat An Elderly Patient
1. Introduction/ Getting to know our Seniors a. Identify common concepts and key terms used when discussing geriatrics b. Distinguish between different venues of senior residence c. Advocate the necessity
Prevalence of Parkinsonism and its aetiological subtypes within patients with movement disorders
Research papers Prevalence of and its aetiological subtypes within patients with movement disorders D G S V D Gajasinghe* AL 2002 batch of students, Faculty of Medicine, University of Colombo Abstract
Chad Christine, MD UCSF
Parkinsonism: Clinical Features and Treatments Parkinson's disease is a condition whose main features are slowed movement, tremor, and gait or balance problems. More than1 million people in the United
Depression is a common biological brain disorder and occurs in 7-12% of all individuals over
Depression is a common biological brain disorder and occurs in 7-12% of all individuals over the age of 65. Specific groups have a much higher rate of depression including the seriously medically ill (20-40%),
Memantine (Ebixa) Drug treatment for Alzheimer s disease
IS 20 October 2011 Information sheet Memantine (Ebixa) Drug treatment for Alzheimer s disease Introduction... 1 How does Ebixa work?... 1 Who might benefit?... 2 What effect might Ebixa have?... 2 How
Welcome to the Medical Risk Webinar: a taster of Assessing and Managing Medical Risk for Insurers courses. 26 April 2013
Welcome to the Medical Risk Webinar: a taster of Assessing and Managing Medical Risk for Insurers courses 26 April 2013 1 Parkinson s Disease & Multiple Sclerosis Dr Nick Niven Jenkins 2 Movement Human
Recognition and Treatment of Depression in Parkinson s Disease
Recognition and Treatment of Depression in Parkinson s Disease Web Ross VA Pacific Islands Health Care System What is depression? Depression is a serious medical condition that affects a person s feelings,
Journal Club. Parkinsonismo iatrogeno
PROGETTO UNIVA 2013 Journal Club Parkinsonismo iatrogeno Pietro Gareri, MD, PhD Geriatra ASP Catanzaro Lamezia Terme 3 Luglio 2013 Drug-induced parkinsonism (DIP) was recognized in the early 1950s as a
PARTNERS IN PARKINSON S. Parkinson s Disease Guide
PARTNERS IN PARKINSON S Parkinson s Disease Guide Each individual travels his or her own journey with Parkinson s disease, often encountering new challenges as symptoms progress and care needs change.
ABC s of Parkinson s Disease 4/29/15 Karen Parenti, MS, PsyD
ABC s of Parkinson s Disease 4/29/15 Karen Parenti, MS, PsyD What is Parkinson s Disease? Parkinson's disease is a progressive disorder of the nervous system that affects movement. It develops gradually,
UNIFIED PARKINSON'S DISEASE RATING SCALE
UNIFIED PARKINSON'S DISEASE RATING SCALE I. MENTATION, BEHAVIOR AND MOOD 1. Intellectual Impairment ne. 1 = Mild. Consistent forgetfulness with partial recollection of events and no other difficulties.
HOW TO HELP HURTING PEOPLE (YOURSELF AND OTHERS)
HOW TO HELP HURTING PEOPLE (YOURSELF AND OTHERS) An Introduction to Biblical Counseling DISCLAIMER DISCLAIMER I m not here to upset you. DISCLAIMER I m not here to upset you. I m not here to give medical
Pharmacological Management of Parkinson s Disease Robert Iansek
GERIATRIC THERAPEUTICS Editors: Associate Professor Michael Woodward, Director, Aged and Residential Care Services, Dr Margaret Bird, Consultant Geriatrician, Mr Rohan Elliott, Clinical Pharmacist, Austin
Chapter 18 Drugs Used for Psychoses Learning Objectives Identify signs and symptoms of psychotic behavior Describe major indications for the use of
Chapter 18 Drugs Used for Psychoses Learning Objectives Identify signs and symptoms of psychotic behavior Describe major indications for the use of antipsychotic agents Identify common adverse effects
Parkinson s disease (PD) is a progressive neurodegenerative
n reports n Advanced Strategies for Treatment of Parkinson s Disease: The Role of Early Treatment Michael W. Jann, PharmD Parkinson s disease (PD) is a progressive neurodegenerative disease associated
cme: The Current Treatment of Parkinson's Disease
cme: The Current Treatment of Parkinson's Disease Lars Wojtecki, Martin Südmeyer, Alfons Schnitzler SUMMARY Introduction: Parkinson s disease is a neurodegenerative disease characterized by akinesia, rigidity,
CLINICAL GUIDELINE FOR THE MANAGEMENT OF INPATIENTS WITH PARKINSONS DISEASE
CLINICAL GUIDELINE FOR THE MANAGEMENT OF INPATIENTS WITH PARKINSON S DISEASE Summary This guideline covers the management of patients with Parkinson s disease including management of medication, confusion,
**Form 1: - Consultant Copy** Telephone Number: Fax Number: Email: Author: Dr Bernard Udeze Pharmacist: Claire Ault Date of issue July 2011
Effective Shared Care Agreement for the treatment of Dementia in Alzheimer s Disease Donepezil tablets / orodispersible tablets (Aricept / Aricept Evess ) These forms (1 and 2) are to be completed by both
Antipsychotic drug prescription for patients with dementia in long-term care. A practice guideline for physicians and caregivers
SUPPLEMENT 1: (Supplementary Material for online publication) Antipsychotic drug prescription for patients with dementia in long-term care. A practice guideline for physicians and caregivers About this
Public Assessment Report. Dopamine agonists: pathological gambling and increased libido TABLE OF CONTENTS
Public Assessment Report Dopamine agonists: pathological gambling and increased libido TABLE OF CONTENTS Summary 2 Introduction 4 Data considered 5 Published literature 9 Discussion 14 Conclusions and
Meeting Report: XX WFN World Congress on Parkinson s Disease and Related Disorders
Meeting Report: XX WFN World Congress on Parkinson s Disease and Related Disorders Karen Frei, Erik Ch. Wolters Abstract: The twentieth World Congress on Parkinson s Disease and Related Disorders was held
What You and Your Family Should Know
Parkinson s Disease: What You and Your Family Should Know Edited by Gale Kittle, RN, MPH Table of Contents Chapter 1: Parkinson s Disease: A Basic Understanding... 3 Chapter 2: Chapter 3: Chapter 4: Chapter
Disorders Considered. A Brief Synopsis of Select Neurological Disorders. Neurological and Psychiatric Symptoms. Neurological Basis
Disorders Considered A Brief Synopsis of Select Neurological Disorders Four neurological disorders are examined to illustrate pathological conditions that can develop related to course material Myasthenia
Parkinson s Disease Medications
Parkinson s Disease Medications By David Houghton, MD, MPH, Howard Hurtig, MD, and Sharon Metz, RN, MPH, with guest author Melanie Brandabur, MD Table of Contents Chapter 1 Introduction to Parkinson s
MOTION AND E-MOTION. Andrea Cavanna MD PhD FRCP
MOTION AND E-MOTION Andrea Cavanna MD PhD FRCP Consultant in Behavioural Neurology, BSMHFT, Birmingham, UK Hon Professor in Neuropsychiatry, Aston University, Birmingham, UK Hon Reader in Neuropsychiatry,
Medication Management of Lewy Body and Parkinson's Dementias
Medication Management of Lewy Body and Parkinson's Dementias Jill Kauer, PharmD, MSPhr, BCPP September 2014 Disclosure Statement I, Jill Kauer, PharmD, MSPhr, BCPP do not have any financial interests or
CLINICAL PRACTICE GUIDELINES FOR PHYSICAL THERAPY IN PATIENTS WITH PARKINSON'S DISEASE
CLINICAL PRACTICE GUIDELINES FOR PHYSICAL THERAPY IN PATIENTS WITH PARKINSON'S DISEASE Charbel MACARI Physical Therapist, AUBMC Master in Neurological Rehabilitation OUTLINE Definition, Epidemiology and
